Tweenvest Stocks

Soleno Therapeutics, Inc. (NasdaqGM: SLNO)

Health Care · Biotechnology · US

$

today · 1Y

Soleno Therapeutics, Inc. (NasdaqGM: SLNO) operates in the Biotechnology industry within the Health Care sector.

trading between 29.43 and 72.99.

Tweenvest scores Soleno Therapeutics, Inc. across four factors: quality 69/100, value 46/100. Its strongest factor is quality.

SLNO price history

Not enough price history to draw a chart yet.

Key figures

Market cap
Revenue (TTM)
$285.01M
P/E
EPS
1.77
Dividend yield
Beta (5Y)
52-week high
$72.99
52-week low
$29.43
Avg volume (3M)
Shares outstanding
Employees
115
Next earnings

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.

ISIN
US8342033094
Founded
1999
Listed since
Nov 13, 2014
Exchange
Nasdaq Global Market
Currency
USD
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$469.68B$265.80+0.00%
Amgen Inc.NasdaqGS: AMGN$239.09B$444.99+0.62%
Gilead Sciences, Inc.NasdaqGS: GILD$184.47B$148.10-0.45%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$140.13B$552.50-0.06%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$83.24B$832.63-0.11%
argenx SEENXTBR: ARGX$64.17B903.40+2.75%
Moderna, Inc.NasdaqGS: MRNA$63.41B$154.84-2.51%
CSL LimitedASX: CSL$59.49BAU$173.64+2.68%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.